The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 06, 2021

Filed:

Nov. 07, 2017
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Guohua Zhao, Princeton, NJ (US);

Pratik Devasthale, Plainsboro, NJ (US);

Xiang-Yang Ye, Princeton, NJ (US);

Kumaravel Selvakumar, Bangalore, IN;

Suresh Dhanusu, Bangalore, IN;

Palanikumar Balasubramanian, Bangalore, IN;

Leatte R. Guernon, Pipersville, PA (US);

Rita Civiello, Killingworth, CT (US);

Xiaojun Han, Cheshire, CT (US);

Michael Frederick Parker, Higganum, CT (US);

Swanee E. Jacutin-Porte, Madison, CT (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 491/04 (2006.01); C07D 519/00 (2006.01); A61P 11/00 (2006.01); A61P 19/10 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61P 11/00 (2018.01); A61P 19/10 (2018.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07D 491/04 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.


Find Patent Forward Citations

Loading…